ClinicalTrials.gg
RecruitingNCT07506109Updated Apr 7, 2026

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

A Phase 2 interventional study of Ipilimumab N01 and Sintilimab in BRAF V600E, Colorectal Cancer and Sintilimab, sponsored by Tianjin Medical University Cancer Institute and Hospital. Recruiting at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Tianjin Medical University Cancer Institute and Hospital · Phase 2, Interventional, and Treatment

How we know · 6 judgments

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing sintilimab in Colorectal Neoplasms — 15 open to participants now, 18 under way, 3 of them phase 3. sintilimab · Colorectal Neoplasms.

Planned enrollment
11th of 26
49 · median 42
Started
2026
with 3 others
Phase 2
19 of 26
10 open now
Primary completion
2027-12
later than 14 of 17 live
Registered
25th of 26
by date
Lead sponsor
2 of 26
Tianjin Medical University Cancer Institute and Hospital

Among the 26 studies testing sintilimab in Colorectal Neoplasms, this one is the 11th largest by planned enrollment, is one of 4 that started in 2026, is one of 19 in phase 2, reaches primary completion later than 14 of the 17 other live ones, and was the 25th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

15 of the 26 studies testing sintilimab in Colorectal Neoplasms are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

About sintilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing sintilimab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

Colorectal cancer (CRC) is the second leading cause of cancer-related death globally. BRAF V600E mutations occur in approximately 12% of metastatic CRC (mCRC) patients, conferring an extremely poor prognosis with a median overall survival (OS) of only 11 months for standard chemotherapy. Most BRAF V600E-mutant mCRC are microsatellite stable (MSS) and do not benefit from single-agent PD-1/PD-L1 inhibition.

Preclinical and clinical evidence indicates that BRAF inhibition in combination with EGFR blockade can induce DNA damage, trigger a deficient mismatch repair (dMMR) phenotype, and increase tumor mutational burden (TMB), thereby sensitizing MSS tumors to immune checkpoint inhibition. This provides a strong rationale for combining BRAF/EGFR inhibitors with anti-PD-1 and anti-CTLA-4 immunotherapy.

This is a single-arm, open-label, Phase II clinical trial. The primary objective is to evaluate the efficacy and safety of the triplet combination of sintilimab (anti-PD-1), ipilimumab N01 (anti-CTLA-4), cetuximab (anti-EGFR), and dabrafenib (BRAF inhibitor) in patients with MSS, BRAF V600E-mutant mCRC.

03

Conditions studied

  • BRAF V600E
  • Colorectal Cancer
  • Sintilimab
  • MSS (Microsatellite Stable)
  • Cetuximab
  • Dabrafenib
  • Ipilimumab N01
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provided written .
  2. Age ≥ 18 years.
  3. or pathologically confirmed colorectal adenocarcinoma.
  4. Documented microsatellite stable (MSS) and BRAF V600E mutation by prior genomic testing.
  5. Locally advanced unresectable disease or distant .
  6. No prior treatment with BRAF/MEK/ERK inhibitors, EGFR inhibitors, or (ICI).
  7. Presence of measurable target lesions per 1.1.
  8. (ECOG) performance status (PS) score of 0 or 1.
  9. Adequate organ function, based on the following laboratory values obtained within 7 days prior to Cycle 1 Day 1:

    1. ≥ 9.0 g/dL.
    2. ≥ 1,500/mm³ (≥ 1.5 × 109/L).
    3. count ≥ 80,000/mm³ (≥ 80 × 109/L).
    4. Serum total ≤ 1.5 × (ULN).
    5. (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN.
    6. Serum creatinine ≤ 1.5 × ULN or ≥ 50 mL/min.
  10. Willing and able to comply with study procedures and visit schedule.

Exclusion criteria

Exclusion Criteria:

  1. Received any approved or systemic anti-tumor therapy within 4 weeks prior to enrollment.
  2. Underwent any surgery or invasive procedure within 4 weeks prior to study initiation (exceptions include venous catheter placement and paracentesis/drainage).
  3. Multiple primary (exceptions include completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, superficial bladder cancer, or any other cancer that has been in complete remission for at least 3 years).
  4. Presence of severe comorbidities or serious medical conditions.
  5. Pregnant or breastfeeding females.
  6. The investigator deems the patient unsuitable for participation in this study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
49 participants (estimated)

Study arms

  • Experimental
    First-line cohort

    Ipilimumab N01+Sintilimab+Cetuximab+Dabrafetinib

    Drug: Ipilimumab N01 · Drug: Sintilimab · Drug: Cetuximab · Drug: Dabrafenib

  • Experimental
    Second-line cohort

    Ipilimumab N01+Sintilimab+Cetuximab+Dabrafetinib

    Drug: Ipilimumab N01 · Drug: Sintilimab · Drug: Cetuximab · Drug: Dabrafenib

Interventions

  • 1mg/kg ivd,q6w or 3mg/kg ivd,q12w followed by maintenance therapy with Ipilimumab N01 1 mg/kg ivd, q6w. The specific dosage and administration schedule should be referred to the relevant study design.

    Also known as: IBI-310

  • 2mg/kg ivd, q3w

    Also known as: IBI-308

  • 500mg/m2 ivd,q2w

  • 150mg po bid

This study also gives IpilimumabStudies of IpilimumabIpilimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the time from study entry until the first occurrence of disease progression or death from any cause, whichever comes first. If a subject does not experience disease progression during the trial, PFS is defined as the date of the last confirmed progression-free survival assessment for that subject.

    Time frame: up to 2 years

Secondary outcomes

  1. Disease Control Rate (DCR)

    DCR: The percentage of patients with a best overall response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) that is maintained for at least 4 weeks, among all patients evaluable for efficacy.

    Time frame: up to 1 year

  2. Objective Response Rate (ORR)

    ORR: The proportion of patients who achieve a reduction in tumor size of a predefined magnitude that is maintained for a specified duration, including cases of CR and PR. Tumor objective response will be assessed in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. All subjects must have measurable tumor lesions at baseline. Efficacy assessments will be categorized as Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) based on RECIST v1.1 criteria.

    Time frame: up to 1 year

  3. Overall Survival (OS)

    OS is defined as the time from study entry to death from any cause. For subjects who are still alive at the final follow-up, OS will be censored at the time of the final follow-up. For lost-to-follow-up subjects, OS will be censored at the time of the last confirmed alive assessment prior to loss to follow-up. OS for censored subjects is defined as the time from study entry to the censoring date.

    Time frame: up to 3 years

  4. Treatment-Related Adverse Events (TRAE)

    Treatment-Related Adverse Events (TRAE) as assessed by CTCAE v5.0, including serious adverse events (SAEs)

    Time frame: up to 3 years

07

Study locations

1 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 21 months is below that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Apr 1, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Jun 2028
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07506109
Responsible party
Sponsor
First posted
Apr 1, 2026
Start date
Mar 1, 2026
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Apr 7, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ipilimumab N01 · Sintilimab · Ipilimumab

Start the discussion